This is a 12-week, open-label, dose-escalation Phase 1b study of a herbal treatment given
orally to subjects with ulcerative colitis. Subjects will be sequentially enrolled to one of
two cohorts in up to two clinical sites. Treatment will be given for 8 weeks and study
duration will be 12 weeks.
1. Age ≥ 18 years and ≤ 75 years.
2. Mild-to-moderate ulcerative colitis (biopsy-proven).
3. Mayo Scoring System Assessment of Ulcerative Colitis Activity score of 3 to 10 at
4. Patients with active disease who are refractory to, intolerant to, or unwilling to
take 5-aminosalicylic acid (5-ASA).
5. Physician's Global Assessment (PGA) Mayo subscore of at least 1 at screening.
6. Mayo rectal bleeding subscore of at least 1 at screening.
7. Endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy
with Mayo mucosal appearance subscore of at least 1 at screening.
8. Female patients of child-bearing potential must have a negative serum pregnancy test
at the screening visit and agree to use two medically reliable methods of
contraception (such as barrier with either spermicide or hormonal contraception)
during the study period.
9. Male patients must be willing to use acceptable contraceptive methods and assure that
their female partners of child-bearing potential use acceptable contraceptive methods
during the study period.
10. Ability to adhere to the study visit schedule and other protocol requirements.
11. Adequate cardiac, renal, and hepatic function as determined by the principal
12. Written informed consent will be obtained before any study procedure is performed.
1. Are nursing or pregnant.
2. Patients who are in critical condition
3. Crohn's disease or indeterminate colitis.
4. Known sensitivity to any ingredients in the study drug.
5. A change in therapy within 2 weeks before the baseline visit.
6. Use of immunomodulators (cyclosporine, mercaptopurine, azathioprine, etc.).
7. Diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease, or
any other unstable medical condition.
8. Any clinically meaningful laboratory abnormality that in the judgment of the
investigator should preclude participation in the study.
9. Impaired renal function (serum creatinine levels >2.0 mg/dL) at screening.
10. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values >1.5
times upper limit of normal at screening.
11. Diagnosis of Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter,
enteropathogenic E. coli in stool.
12. Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen
(HBsAg) at screening.
13. Active malignancy (except basal cell carcinoma).
14. Active alcohol or drug abuse.
15. Tobacco smoking within 2 weeks before study entry.